Nucleic Acid Therapeutics CDMO Market Size, Share & Trends Analysis Report By Therapy / Modality Type (mRNA-based Therapeutics, DNA / Plasmid DNA Therapeutics, siRNA (Small Interfering RNA), Antisense Oligonucleotides (ASOs), Gene Therapy Products, Others), By Service Type (Process Development & Optimization, Drug Product (Formulation, Fill & Finish), Analytical & Quality Control (QC) Services, Regulatory Support & Technology Transfer, Packaging & Fill–Finish Services), By Workflow Stage (Preclinical Development, Clinical Manufacturing (Phase I–III), Commercial-Scale Production), By End User, By Therapeutic Area, By Region and By Segments Forecasts, 2025-2034
Segmentation Of Nucleic Acid Therapeutics CDMO Market:
Nucleic Acid Therapeutics CDMO Market By Therapy / Modality Type-
- mRNA-based Therapeutics
- DNA / Plasmid DNA Therapeutics
- siRNA (Small Interfering RNA)
- Antisense Oligonucleotides (ASOs)
- Gene Therapy Products
- Others
Nucleic Acid Therapeutics CDMO Market By Service Type-
- Process Development & Optimization
- cGMP Manufacturing
- Drug Substance (API)
- Drug Product (Formulation, Fill & Finish)
- Analytical & Quality Control (QC) Services
- Regulatory Support & Technology Transfer
- Packaging & Fill–Finish Services
Nucleic Acid Therapeutics CDMO Market By Workflow Stage-
- Preclinical Development
- Clinical Manufacturing (Phase I–III)
- Commercial-Scale Production
Nucleic Acid Therapeutics CDMO Market By End-User-
- Biopharmaceutical / Biotechnology Companies
- Pharmaceutical Companies
- Academic & Research Institutes
Nucleic Acid Therapeutics CDMO Market By Therapeutic Area-
- Oncology
- Infectious Diseases
- Rare Genetic Disorders
- Cardiovascular & Metabolic Disorders
- Neurological Disorders
Nucleic Acid Therapeutics CDMO Market By Region-
North America-
- The US
- Canada
Europe-
- Germany
- The UK
- France
- Italy
- Spain
- Rest of Europe
Asia-Pacific-
- China
- Japan
- India
- South Korea
- South East Asia
- Rest of Asia Pacific
Latin America-
- Brazil
- Mexico
- Argentina
- Rest of Latin America
Middle East & Africa-
- GCC Countries
- South Africa
- Rest of Middle East and Africa
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global Nucleic Acid Therapeutics CDMO Market Snapshot
Chapter 4. Global Nucleic Acid Therapeutics CDMO Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Investment and Funding Analysis
4.6. Industry Analysis – Porter’s Five Forces Analysis
4.7. Competitive Landscape & Market Share Analysis
4.8. Impact of Covid-19 Analysis
Chapter 5. Market Segmentation 1: by Therapy / Modality Type Estimates & Trend Analysis
5.1. by Therapy / Modality Type & Market Share, 2024 & 2034
5.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2021 to 2034 for the following by Therapy / Modality Type:
5.2.1. mRNA-based Therapeutics
5.2.2. DNA / Plasmid DNA Therapeutics
5.2.3. siRNA (Small Interfering RNA)
5.2.4. Antisense Oligonucleotides (ASOs)
5.2.5. Gene Therapy Products
5.2.6. Others
Chapter 6. Market Segmentation 2: by Service Type Estimates & Trend Analysis
6.1. by Service Type & Market Share, 2024 & 2034
6.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2021 to 2034 for the following by Service Type:
6.2.1. Process Development & Optimization
6.2.2. Drug Product (Formulation, Fill & Finish)
6.2.3. Analytical & Quality Control (QC) Services
6.2.4. Regulatory Support & Technology Transfer
6.2.5. Packaging & Fill–Finish Services
Chapter 7. Market Segmentation 3: by Workflow Stage Estimates & Trend Analysis
7.1. by Workflow Stage & Market Share, 2024 & 2034
7.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2021 to 2034 for the following by Workflow Stage:
7.2.1. Preclinical Development
7.2.2. Clinical Manufacturing (Phase I–III)
7.2.3. Commercial-Scale Production
Chapter 8. Market Segmentation 4: by End user Estimates & Trend Analysis
8.1. by End user & Market Share, 2024 & 2034
8.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2021 to 2034 for the following by End user:
8.2.1. Biopharmaceutical / Biotechnology Companies
8.2.2. Pharmaceutical Companies
8.2.3. Academic & Research Institutes
Chapter 9. Market Segmentation 5: by Therapeutic Area Estimates & Trend Analysis
9.1. by Therapeutic Area & Market Share, 2024 & 2034
9.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2021 to 2034 for the following by Therapeutic Area:
9.2.1. Oncology
9.2.2. Infectious Diseases
9.2.3. Rare Genetic Disorders
9.2.4. Cardiovascular & Metabolic Disorders
9.2.5. Neurological Disorders
Chapter 10. Nucleic Acid Therapeutics CDMO Market Segmentation 6: Regional Estimates & Trend Analysis
10.1. North America
10.1.1. North America Nucleic Acid Therapeutics CDMO Market Revenue (US$ Million) Estimates and Forecasts by Therapy / Modality Type, 2021-2034
10.1.2. North America Nucleic Acid Therapeutics CDMO Market Revenue (US$ Million) Estimates and Forecasts by Service Type, 2021-2034
10.1.3. North America Nucleic Acid Therapeutics CDMO Market Revenue (US$ Million) Estimates and Forecasts by Workflow Stage, 2021-2034
10.1.4. North America Nucleic Acid Therapeutics CDMO Market Revenue (US$ Million) Estimates and Forecasts by End user, 2021-2034
10.1.5. North America Nucleic Acid Therapeutics CDMO Market Revenue (US$ Million) Estimates and Forecasts by Therapeutic area, 2021-2034
10.1.6. North America Nucleic Acid Therapeutics CDMO Market Revenue (US$ Million) Estimates and Forecasts by country, 2021-2034
10.2. Europe
10.2.1. Europe Nucleic Acid Therapeutics CDMO Market Revenue (US$ Million) Estimates and Forecasts by Therapy / Modality Type, 2021-2034
10.2.2. Europe Nucleic Acid Therapeutics CDMO Market Revenue (US$ Million) Estimates and Forecasts by Service Type, 2021-2034
10.2.3. Europe Nucleic Acid Therapeutics CDMO Market Revenue (US$ Million) Estimates and Forecasts by Workflow Stage, 2021-2034
10.2.4. Europe Nucleic Acid Therapeutics CDMO Market Revenue (US$ Million) Estimates and Forecasts by End user, 2021-2034
10.2.5. Europe Nucleic Acid Therapeutics CDMO Market Revenue (US$ Million) Estimates and Forecasts by Therapeutic area, 2021-2034
10.2.6. Europe Nucleic Acid Therapeutics CDMO Market Revenue (US$ Million) Estimates and Forecasts by country, 2021-2034
10.3. Asia Pacific
10.3.1. Asia Pacific Nucleic Acid Therapeutics CDMO Market Revenue (US$ Million) Estimates and Forecasts by Therapy / Modality Type, 2021-2034
10.3.2. Asia Pacific Nucleic Acid Therapeutics CDMO Market Revenue (US$ Million) Estimates and Forecasts by Service Type, 2021-2034
10.3.3. Asia-Pacific Nucleic Acid Therapeutics CDMO Market Revenue (US$ Million) Estimates and Forecasts by Workflow Stage, 2021-2034
10.3.4. Asia-Pacific Nucleic Acid Therapeutics CDMO Market Revenue (US$ Million) Estimates and Forecasts by End user, 2021-2034
10.3.5. Asia Pacific Nucleic Acid Therapeutics CDMO Market Revenue (US$ Million) Estimates and Forecasts by Therapeutic area, 2021-2034
10.3.6. Asia Pacific Nucleic Acid Therapeutics CDMO Market Revenue (US$ Million) Estimates and Forecasts by country, 2021-2034
10.4. Latin America
10.4.1. Latin America Nucleic Acid Therapeutics CDMO Market Revenue (US$ Million) Estimates and Forecasts by Therapy / Modality Type, 2021-2034
10.4.2. Latin America Nucleic Acid Therapeutics CDMO Market Revenue (US$ Million) Estimates and Forecasts by Service Type, 2021-2034
10.4.3. Latin America Nucleic Acid Therapeutics CDMO Market Revenue (US$ Million) Estimates and Forecasts by Workflow Stage, 2021-2034
10.4.4. Latin America Nucleic Acid Therapeutics CDMO Market Revenue (US$ Million) Estimates and Forecasts by End user, 2021-2034
10.4.5. Latin America Nucleic Acid Therapeutics CDMO Market Revenue (US$ Million) Estimates and Forecasts by Therapeutic area, 2021-2034
10.4.6. Latin America Nucleic Acid Therapeutics CDMO Market Revenue (US$ Million) Estimates and Forecasts by country, 2021-2034
10.5. Middle East & Africa
10.5.1. Middle East & Africa Nucleic Acid Therapeutics CDMO Market Revenue (US$ Million) Estimates and Forecasts by Therapy / Modality Type, 2021-2034
10.5.2. Middle East & Africa Nucleic Acid Therapeutics CDMO Market Revenue (US$ Million) Estimates and Forecasts by Service Type, 2021-2034
10.5.3. Middle East & Africa Nucleic Acid Therapeutics CDMO Market Revenue (US$ Million) Estimates and Forecasts by Workflow Stage, 2021-2034
10.5.4. Middle East & Africa Nucleic Acid Therapeutics CDMO Market Revenue (US$ Million) Estimates and Forecasts by End user, 2021-2034
10.5.5. Middle East & Africa Nucleic Acid Therapeutics CDMO Market Revenue (US$ Million) Estimates and Forecasts by Therapeutic area, 2021-2034
10.5.6. Middle East & Africa Nucleic Acid Therapeutics CDMO Market Revenue (US$ Million) Estimates and Forecasts by country, 2021-2034
Chapter 11. Competitive Landscape
11.1. Major Mergers and Acquisitions/Strategic Alliances
11.2. Company Profiles
11.2.1. Agilent Technologies, Inc.
11.2.2. Bachem AG
11.2.3. Ajinomoto Bio-Pharma Services
11.2.4. BioSpring GmbH
11.2.5. Exothera SA
11.2.6. Helix Biotech
11.2.7. LGC Group / Axolabs GmbH
11.2.8. Thermo Fisher Scientific Inc. (Patheon)
11.2.9. Danaher Corporation (Aldevron)
11.2.10. WuXi AppTec Co., Ltd.
11.2.11. Merck KGaA (MilliporeSigma Life Science)
11.2.12. Curia Global, Inc. (formerly AMRI)
11.2.13. KNC Laboratories Co., Ltd.
11.2.14. Univercells / Univercells Technologies
11.2.15. Integrated DNA Technologies (IDT, Danaher subsidiary)
11.2.16. Evonik Industries AG (Health Care Business Line)
11.2.17. Ology Bioservices (now part of National Resilience, Inc.)
11.2.18. TriLink BioTechnologies (Maravai LifeSciences)
11.2.19. AGC Biologics, Inc.
11.2.20. Aurigene Pharmaceutical Services Ltd.
11.2.21. PolyPeptide Group AG
11.2.22. Eurofins Scientific SE (Eurofins Genomics Division)
11.2.23. Kaneka Eurogentec S.A.
11.2.24. Nitto Denko Avecia Inc.
11.2.25. ST Pharm Co., Ltd.
11.2.26. Other Prominent Players
Research Design and Approach
This study employed a multi-step, mixed-method research approach that integrates:
- Secondary research
- Primary research
- Data triangulation
- Hybrid top-down and bottom-up modelling
- Forecasting and scenario analysis
This approach ensures a balanced and validated understanding of both macro- and micro-level market factors influencing the market.
Secondary Research
Secondary research for this study involved the collection, review, and analysis of publicly available and paid data sources to build the initial fact base, understand historical market behaviour, identify data gaps, and refine the hypotheses for primary research.
Sources Consulted
Secondary data for the market study was gathered from multiple credible sources, including:
- Government databases, regulatory bodies, and public institutions
- International organizations (WHO, OECD, IMF, World Bank, etc.)
- Commercial and paid databases
- Industry associations, trade publications, and technical journals
- Company annual reports, investor presentations, press releases, and SEC filings
- Academic research papers, patents, and scientific literature
- Previous market research publications and syndicated reports
These sources were used to compile historical data, market volumes/prices, industry trends, technological developments, and competitive insights.
Primary Research
Primary research was conducted to validate secondary data, understand real-time market dynamics, capture price points and adoption trends, and verify the assumptions used in the market modelling.
Stakeholders Interviewed
Primary interviews for this study involved:
- Manufacturers and suppliers in the market value chain
- Distributors, channel partners, and integrators
- End-users / customers (e.g., hospitals, labs, enterprises, consumers, etc., depending on the market)
- Industry experts, technology specialists, consultants, and regulatory professionals
- Senior executives (CEOs, CTOs, VPs, Directors) and product managers
Interview Process
Interviews were conducted via:
- Structured and semi-structured questionnaires
- Telephonic and video interactions
- Email correspondences
- Expert consultation sessions
Primary insights were incorporated into demand modelling, pricing analysis, technology evaluation, and market share estimation.
Data Processing, Normalization, and Validation
All collected data were processed and normalized to ensure consistency and comparability across regions and time frames.
The data validation process included:
- Standardization of units (currency conversions, volume units, inflation adjustments)
- Cross-verification of data points across multiple secondary sources
- Normalization of inconsistent datasets
- Identification and resolution of data gaps
- Outlier detection and removal through algorithmic and manual checks
- Plausibility and coherence checks across segments and geographies
This ensured that the dataset used for modelling was clean, robust, and reliable.
Market Size Estimation and Data Triangulation
Bottom-Up Approach
The bottom-up approach involved aggregating segment-level data, such as:
- Company revenues
- Product-level sales
- Installed base/usage volumes
- Adoption and penetration rates
- Pricing analysis
This method was primarily used when detailed micro-level market data were available.
Top-Down Approach
The top-down approach used macro-level indicators:
- Parent market benchmarks
- Global/regional industry trends
- Economic indicators (GDP, demographics, spending patterns)
- Penetration and usage ratios
This approach was used for segments where granular data were limited or inconsistent.
Hybrid Triangulation Approach
To ensure accuracy, a triangulated hybrid model was used. This included:
- Reconciling top-down and bottom-up estimates
- Cross-checking revenues, volumes, and pricing assumptions
- Incorporating expert insights to validate segment splits and adoption rates
This multi-angle validation yielded the final market size.
Forecasting Framework and Scenario Modelling
Market forecasts were developed using a combination of time-series modelling, adoption curve analysis, and driver-based forecasting tools.
Forecasting Methods
- Time-series modelling
- S-curve and diffusion models (for emerging technologies)
- Driver-based forecasting (GDP, disposable income, adoption rates, regulatory changes)
- Price elasticity models
- Market maturity and lifecycle-based projections
Scenario Analysis
Given inherent uncertainties, three scenarios were constructed:
- Base-Case Scenario: Expected trajectory under current conditions
- Optimistic Scenario: High adoption, favourable regulation, strong economic tailwinds
- Conservative Scenario: Slow adoption, regulatory delays, economic constraints
Sensitivity testing was conducted on key variables, including pricing, demand elasticity, and regional adoption.
Request Customization
Add countries, segments, company profiles, or extend forecast — free 10% customization with purchase.
Customize This Report →Enquire Before Buying
Speak with our analyst team about scope, methodology, pricing, or deliverable formats.
Enquire Now →Frequently Asked Questions
Agilent Technologies, Inc., Bachem AG, Ajinomoto Bio-Pharma Services, BioSpring GmbH, Exothera SA, Helix Biotech, LGC Group / Axolabs GmbH, Thermo Fisher Scientific Inc. (Patheon), Danaher Corporation (Aldevron), WuXi AppTec Co., Ltd., Merck KGaA (MilliporeSigma Life Science), Curia Global, Inc. (formerly AMRI), KNC Laboratories Co., Ltd., Univercells / Univercells Technologies, Integrated DNA Technologies (IDT, Danaher subsidiary), Evonik Industries AG (Health Care Business Line), Ology Bioservices (now part of National Resilience, Inc.), TriLink BioTechnologies (Maravai LifeSciences), AGC Biologics, Inc., Aurigene Pharmaceutical Services Ltd., PolyPeptide Group AG, Eurofins Scientific SE (Eurofins Genomics Division), Kaneka Eurogentec S.A., Nitto Denko Avecia Inc., ST Pharm Co., Ltd., Others
Nucleic Acid Therapeutics CDMO Market Size is valued at USD 2,540.9 Million in 2024 and is predicted to reach USD 8,688.2 Million by the year 2034
Nucleic Acid Therapeutics CDMO Market is expected to grow at an 13.2 % CAGR during the forecast period for 2025-2034.
Therapy / Modality Type, Service Type, Workflow Stage, End-User and Therapeutic Area are the key segments of the Nucleic Acid Therapeutics CDMO Market.
North America region is leading the Nucleic Acid Therapeutics CDMO Market.